Evidence map›Paper›PMID 40295435›Full record

ArticleBulletin of experimental biology and medicine2025

Hepatoprotective Properties of New Xymedon Derivatives with a Modified Structural Moiety.

A B Vyshtakalyuk, A A Parfenov, V E Semenov, M S Shashin, I V Galyametdinova, M V Kriulina, V V Zobov

Abstract read
PubMed Publisher
In one paragraph

Article in Bulletin of experimental biology and medicine, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

A B VyshtakalyukArbuzov Institute of Organic and Physical Chemistry - Separated Division of Kazan Scientific Center, Russian Academy of Sciences, Kazan, Russia. alex.vysh@mail.ru.
A A ParfenovArbuzov Institute of Organic and Physical Chemistry - Separated Division of Kazan Scientific Center, Russian Academy of Sciences, Kazan, Russia.
V E SemenovArbuzov Institute of Organic and Physical Chemistry - Separated Division of Kazan Scientific Center, Russian Academy of Sciences, Kazan, Russia.
M S ShashinArbuzov Institute of Organic and Physical Chemistry - Separated Division of Kazan Scientific Center, Russian Academy of Sciences, Kazan, Russia.
I V GalyametdinovaArbuzov Institute of Organic and Physical Chemistry - Separated Division of Kazan Scientific Center, Russian Academy of Sciences, Kazan, Russia.
M V KriulinaArbuzov Institute of Organic and Physical Chemistry - Separated Division of Kazan Scientific Center, Russian Academy of Sciences, Kazan, Russia.
V V ZobovArbuzov Institute of Organic and Physical Chemistry - Separated Division of Kazan Scientific Center, Russian Academy of Sciences, Kazan, Russia.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

We studied the hepatoprotective properties of new modifications of the Russian drug, the regeneration stimulator Xymedon (1,2-dihydro-4,6-dimethyl-1-(2-hydroxyethyl)-pyrimidin-2-one) (1): 1,2-dihydro-4,6-dimethyl-(1-(2-((hydroxyethyl)amino)ethyl)-pyrimidin-2-one (2) and 1,2-dihydro-4,6-dimethyl-1-propyl-pyrimidin-2-one (3). First, cytotoxicity and cytoprotective effects of the compounds were assessed on Chang Liver, HepG2, and WI-38 human cell lines, and then, hepatoprotective activity in vivo was evaluated on the model of toxic CCl

Indexed as

Chemical and Drug Induced Liver InjuryLiverProtective AgentsPyrimidinesAnimalsCarbon TetrachlorideCell LineCell SurvivalGalactosamineHep G2 CellsHumansMaleRatsRats, WistarCarbon TetrachlorideGalactosamineProtective AgentsPyrimidinescytotoxicityhepatoprotective activitypyrimidin-2-onesxymedon

Identifiers

PMID40295435

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.